Medtronic (NYSE:MDT) issued its quarterly earnings data on Tuesday. The medical technology company reported $1.29 earnings per share for the quarter, beating analysts' consensus estimates of $1.15 by $0.14, RTT News reports. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.77 billion. Medtronic had a return on equity of 9.71% and a net margin of 12.69%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $1.44 earnings per share.
Shares of NYSE:MDT traded up $3.17 during trading on Tuesday, reaching $118.92. The stock had a trading volume of 46,884 shares, compared to its average volume of 4,571,249. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.79 and a current ratio of 2.16. The business has a fifty day moving average price of $116.82 and a 200-day moving average price of $110.18. The stock has a market cap of $160.07 billion, a PE ratio of 44.18, a PEG ratio of 3.65 and a beta of 0.70. Medtronic has a 1-year low of $72.13 and a 1-year high of $120.53.
In other Medtronic news, SVP Carol A. Surface sold 15,000 shares of the business's stock in a transaction on Monday, December 28th. The stock was sold at an average price of $114.90, for a total transaction of $1,723,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Robert John White sold 10,930 shares of the business's stock in a transaction on Friday, December 18th. The stock was sold at an average price of $115.46, for a total value of $1,261,977.80. Following the transaction, the executive vice president now directly owns 55,852 shares in the company, valued at approximately $6,448,671.92. The disclosure for this sale can be found here. Insiders own 0.52% of the company's stock.
Several brokerages have weighed in on MDT. Oppenheimer raised their price target on Medtronic from $122.00 to $128.00 and gave the stock an "outperform" rating in a report on Wednesday, November 25th. SVB Leerink raised their price target on Medtronic from $110.00 to $123.00 and gave the stock a "market perform" rating in a report on Wednesday, November 25th. Raymond James raised their price target on Medtronic from $115.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, November 25th. Morgan Stanley raised Medtronic from an "equal weight" rating to an "overweight" rating and set a $140.00 price target for the company in a report on Tuesday, December 15th. Finally, The Goldman Sachs Group raised Medtronic from a "sell" rating to a "neutral" rating and raised their price target for the stock from $100.00 to $119.00 in a report on Tuesday, December 15th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of "Buy" and a consensus price target of $120.93.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.
Recommended Story: How can investors invest in the Euro STOXX 50 Index?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Energy Stocks Analysts Love the Most
There are more than 450 energy companies traded on public markets. Given the sheer number of pipeline companies, power plant operators, oil and gas production companies, and other energy stocks, it can be hard to identify which energy companies will outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 8,000 distinct recommendations for energy companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same energy stock.
This slide show lists the 15 energy companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Energy Stocks Analysts Love the Most".